Cargando…

The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer

BACKGROUND: Around 50% of women receiving Aromatase Inhibitors (AIs) develop musculoskeletal symptoms which may become severe causing interruption of treatment. Patients with AI-induced arthralgia had higher rates of joint effusions and fluid in the tendons, so use of diuretics may be helpful. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhanafy, Alshimaa Mahmoud, Labeeb, Alaa, Khalil, Ashraf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428535/ https://www.ncbi.nlm.nih.gov/pubmed/30583679 http://dx.doi.org/10.31557/APJCP.2018.19.12.3525

Ejemplares similares

Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume
por: Alhanafy, Alshimaa Mahmoud, et al.
Publicado: (2018)

Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors
por: Park, Jin Young, et al.
Publicado: (2013)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Vitamin D in the Prevention of Aromatase Inhibitor–Induced Musculoskeletal Symptoms: Is It Ready for Practice?
por: Brant, Jeannine
Publicado: (2012)

Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms
por: Henry, N Lynn, et al.
Publicado: (2021)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
por: Khan, Qamar J., et al.
Publicado: (2010)

Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy
por: Chavarri-Guerra, Y, et al.
Publicado: (2014)

The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors :a systematic review and meta-analysis
por: Lu, Geling, et al.
Publicado: (2019)

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
por: Hyder, Tara, et al.
Publicado: (2021)

Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor
por: Shioi, Yoshihiro, et al.
Publicado: (2014)

Indications of Clinical and Genetic Predictors for Aromatase Inhibitors Related Musculoskeletal Adverse Events in Chinese Han Women with Breast Cancer
por: Wang, Jingxuan, et al.
Publicado: (2013)

Non Size Based Morphology Criteria for Assessment of Response in Patients with Liver Metastases of Gastrointestinal Origin Receiving Systemic Treatment
por: Alhanafy, Alshimaa, et al.
Publicado: (2018)

Effectiveness of intervention for aromatase inhibitor-associated musculoskeletal symptoms: A protocol for systematic review and meta-analysis
por: Meng, Hui, et al.
Publicado: (2022)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer
por: Hertz, Daniel L., et al.
Publicado: (2021)

Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities
por: Grigorian, Nelly, et al.
Publicado: (2022)

A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
por: Liu, Lei, et al.
Publicado: (2013)

Complementary or Alternative Medicine as Possible Determinant of Decreased Persistence to Aromatase Inhibitor Therapy among Older Women with Non-Metastatic Breast Cancer
por: Huiart, Laetitia, et al.
Publicado: (2013)

Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
por: Tenti, Sara, et al.
Publicado: (2020)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer
por: Dempsey, Jacqueline M., et al.
Publicado: (2018)

What are the effects of systemic therapies for the prevention and treatment of aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer? - A Cochrane Review summary with commentary
por: Sen, Ekin Ilke
Publicado: (2022)

Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer
por: Soliman, Shimaa El-Shafey, et al.
Publicado: (2018)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study
por: Henry, N L, et al.
Publicado: (2010)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients
por: Wang, Jingxuan, et al.
Publicado: (2015)

Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients
por: Hack, C.C., et al.
Publicado: (2020)

Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
por: Lønning, P. E.
Publicado: (1998)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
por: Lee, June Koo, et al.
Publicado: (2013)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study
por: de Sire, Alessandro, et al.
Publicado: (2021)

Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
por: Gaillard, Stéphanie, et al.
Publicado: (2011)

Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model
por: Young, Nicholas A., et al.
Publicado: (2022)

The 5-Year Disease-Free Survival of Third Generation Aromatase Inhibitor for Postmenopausal Women with HR-Positive HER2-Negative Non-Metastatic Breast Cancer
por: Etikasari, Ria, et al.
Publicado: (2023)

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer
por: DeMichele, Angela, et al.
Publicado: (2023)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tkl2klcbq1t67a7m9nga2tm1p0